Your AI-Trained Oncology Knowledge Connection!
Enzalutamide plus leuprolide acetate led to a 40.3% lower risk of death vs leuprolide acetate alone in high-risk, biochemically recurrent prostate cancer.
The addition of relacorilant to nab-paclitaxel produced a PFS benefit vs nab-paclitaxel alone in PROC with a history of PARP inhibitor exposure.
Sacituzumab govitecan reduced the risk for disease progression or death by 38% vs chemotherapy in previously untreated, locally advanced, unresectable or metastatic triple-negative breast cancer.
Capivasertib plus abiraterone acetate, prednisone, and androgen deprivation therapy was active in PTEN-deficient de novo metastatic HSPC.
NAPISTAR1-01 showed enduring benefit with TUB-040 in patients with platinum-resistant high-grade serous ovarian cancer.
I-DXd showed intracranial efficacy and manageable safety in ES-SCLC with brain metastases, per data from the IDeate-Lung01 study.
Pembrolizumab plus lenvatinib was safe and active in HLA-A*02:01–negative and –positive uveal melanoma.
Gedatolisib plus fulvestrant, with or without palbociclib, improved PFS in pretreated, HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer.
Sac-TMT bested chemotherapy in terms of PFS in previously treated HR+, HER2– metastatic breast cancer.
Enfortumab vedotin plus pembrolizumab significantly improved survival and pCR vs surgery alone in cisplatin-ineligible MIBC per KEYNOTE-905 data.
Neoadjuvant T-DXd followed by THP improved pathological complete response rate in high-risk, HER2-positive early-stage breast cancer.
The SKYSCRAPER-03 trial missed the end point of a PFS benefit with tiragolumab plus atezolizumab vs durvalumab consolidation in advanced NSCLC.
Pembrolizumab and paclitaxel with or without bevacizumab led to PFS and OS benefits vs placebo in place of pembrolizumab in recurrent, PD-L1–positive PROC.
Findigs from DeLLphi-304 support the use of tarlatamab as a standard of care for all patients with second-line small cell lung cancer.
Invikafusp alfa demonstrated early signals of antitumor activity across a range of biomarker-enriched patients with solid tumors.
Adjuvant nivolumab significantly extended RFS vs ipilimumab in patients with resected stage IIIB to IIIC or IV melanoma.
T-DXd significantly improved IDFS vs T-DM1 in high-risk, HER2-positive primary breast cancer with residual invasive disease after neoadjuvant therapy.
Adjuvant cemiplimab and placebo were associated with similar rates of second primary tumors in high-risk CSCC.
177-Lu-edotretide significantly improved survival outcomes vs everolimus for the treatment of patients with grade 1/2 GEP-NETs.
BNT111 plus cemiplimab achieved an 18.1% ORR in PD-(L)1–refractory melanoma, meeting its primary end point in the phase 2 BNT111-01 trial.
First-line treatment with tarlatamab plus chemoimmunotherapy and anti–PD-L1 maintenance therapy generated durable responses in patients with ES-SCLC.
Datopotamab deruxtecan plus rilvegostomig was active in cisplatin-ineligible and platinum-pretreated locally advanced or metastatic urothelial cancer.
Lenvatinib plus everolimus improved PFS vs cabozantinib in metastatic clear cell renal cell carcinoma after progression on a PD-1 inhibitor.
Giredestrant plus everolimus improved progression-free survival in ER-positive, HER2-negative advanced breast cancer after a prior CDK4/6 inhibitor.
Belzutifan plus pembrolizumab and lenvatinib improved efficacy outcomes compared with multiple other pembrolizumab-based triplet regimens in advanced clear cell renal cell carcinoma.
RNAseq-defined clusters guided treatment selection in metastatic ccRCC in the phase 2 OPTIC trial, yielding a 76% ORR with cabozantinib plus nivolumab.
Fruquintinib plus sintilimab significantly extended progression-free survival in advanced RCC following first-line VEGFR TKI therapy.
Long-term data demonstrated durable responses with pimicotinib in tenosynovial giant cell tumor.
regorafenib/nivolumab may encourage a search for more non-chemotherapy combinations for gastric cancer.
Osimertinib plus chemotherapy improved OS vs osimertinib alone in EGFR-mutated advanced non–small lung cancer, irrespective of poor prognostic factors.
